Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer

Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer

Assessment of programmed cell death-ligand 1 (PD-L1) expression by immunohistochemistry (IHC) is the definite diagnostic test to guide treatment for patients with advanced-stage non-small cell lung cancer. Intratumoral heterogeneity and discrepancy of PD-L1 expression between primary and metastatic...

Full description

Bibliographic Details
Main Authors:	Lajos Pusztai, Richard Huang, Shakti Ramkissoon, Jeffrey S Ross, Konstantinos Syrigos, Myrto K Moutafi, Weiwei Tao, James Haberberger, Ioannis A Vathiotis
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/9/4/e002230.full

Similar Items

Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
by: Ioannis A. Vathiotis, et al.
Published: (2021-05-01)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
by: Brian Alexander, et al.
Published: (2020-07-01)

The Role of Genetics in Sporadic GEP-NETs: A Comprehensive Review of the Literature
by: Fotopoulos George, et al.
Published: (2017-06-01)

Hemangioblastoma in the Lung: Metastatic or Primary Lesions?
by: Li Lu, et al.
Published: (2014-01-01)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
by: Ping-Chih Hsu, et al.
Published: (2020-02-01)

Tumor Dormancy: Implications for Invasion and Metastasis
by: Georgia Gomatou, et al.
Published: (2021-05-01)

Lung Nodules in Melanoma Patients: Morphologic Criteria to Differentiate Non-Metastatic and Metastatic Lesions
by: Simone Alexandra Stadelmann, et al.
Published: (2021-05-01)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
by: Brian Alexander, et al.
Published: (2020-07-01)

Clinical and surgical-pathological staging in early non-small cell lung cancer
by: Ioannis Koukis, et al.
Published: (2013-12-01)

Lung malignancy in prostate cancer: A report of both metastatic and primary lung lesions
by: Lael Reinstatler, et al.
Published: (2018-01-01)

Recent Advances in Molecular Diagnosis of Thyroid Cancer
by: Ioannis Legakis, et al.
Published: (2011-01-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors
by: Lori A. Ramkissoon, et al.
Published: (2020-10-01)

Next-Generation Sequencing in Order to Better Characterize a BRCA Variant of Uncertain Significance
by: Steven Sorscher, et al.
Published: (2017-07-01)

Metastatic Lesions to the Liver
by: Jorge Ortiz, et al.
Published: (2013-01-01)

Metastatic lesions of tongue
by: Subhashish Das
Published: (2021-01-01)

Sampling versus systematic full lymphatic dissection in surgical treatment of non-small cell lung cancer
by: Georgios Koulaxouzidis, et al.
Published: (2013-06-01)

Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer
by: Ioannis A. Vathiotis, et al.
Published: (2021-03-01)

Regulation of the growth of human breast cancer by tumour necrosis factor-alpha
by: Pusztai, Lajos
Published: (1993)

Treatment of metastatic brain lesion
by: A. M. Zaytsev, et al.
Published: (2015-06-01)

Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
by: Sayuri Nakamura, et al.
Published: (2017-01-01)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
by: Wang S, et al.
Published: (2020-01-01)

ANALYSIS OF THE PREVALENCE OF METASTATIC CHOROIDAL LESIONS
by: Ya. V. Parmon, et al.
Published: (2017-01-01)

The radiological appearance of metastatic cystic lesions
by: Pieter Barnardt, et al.
Published: (2011-12-01)

Percutaneous acetabuloplasty for metastatic acetabular lesions
by: Logroscino Giandomenico, et al.
Published: (2008-05-01)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
by: Zhang Y, et al.
Published: (2014-04-01)

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients
by: Chen J, et al.
Published: (2017-04-01)

Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
by: Cheng Xu, et al.
Published: (2018-01-01)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
by: Mariya Rozenblit, et al.
Published: (2021-01-01)

Effectiveness of Combined Anti-programmed Death-ligand 1 Therapy and Radiotherapy for Metastatic Merkel Cell Carcinoma: Two Case Reports
by: Kanako Tsunoda, et al.
Published: (2020-08-01)

Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms
by: Zhou Tong, et al.
Published: (2021-05-01)

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
by: Yuan Gao, et al.
Published: (2017-07-01)

Voltage-gated Na+ channel expression in human breast cancer cell lines in relation to metastatic potential
by: Chioni, Athina-Myrto
Published: (2007)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
by: Wei-Bo Yu, et al.
Published: (2019-09-01)

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
by: Chang Hyun Nam, et al.
Published: (2021-07-01)

Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
by: Ha-Young Park, M.D., et al.
Published: (2019-07-01)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
by: Emmanuel Acheampong, et al.
Published: (2019-06-01)

Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon
by: Ghina Fakhri, et al.
Published: (2021-09-01)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
by: Sheng-Kai Liang, et al.
Published: (2021-09-01)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
by: Giuseppe Bronte, et al.
Published: (2021-05-01)